Navigation Links
Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
Date:4/15/2008

NANJING, China, April 15 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2008 first quarter results on Tuesday, May 6, 2008, before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2008 first quarter results on Tuesday, May 6, at 8 a.m. EDT (Tuesday, May 6, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

United States toll-free dial-in number: +1.866.510.0712

United States dial-in number: +1.617.597.5380

China toll-free dial-in number: 10.800.130.0399

Hong Kong dial-in number: +852.3002.1672

Please ask to be connected to Simcere's Q1 2008 Earnings Call and provide the following passcode: 95590725. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1.888.286.8010

United States dial-in number: +1.617.801.6888

The passcode for replay participants is: 67719578. The telephone replay also will be archived on the "Investor Relations" section of the company's Web site at http://www.simcere.com for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 35 pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com.

Investor and Media Contacts:

In China:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556 6666 ext. 8818

E-mail: zhaozhigang@simcere.com

Kejia Wu

Brunswick Group

Tel: +8610 6566 4651

Email: kwu@brunswickgroup.com

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852 3512 5033

Email: jlo@brunswickgroup.com

In the United States:

Michael Guerin

Brunswick Group

Tel: +1-212-333-3810

E-mail: mguerin@brunswickgroup.com


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... ... Driving Dynamics Inc., announced today it has been selected as a 2017 ... its mission to continually monitor the training marketplace for the best providers of training ... and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard sets out ... organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released in 2015 ... with a deadline of September 2018. , As described in this ...
(Date:9/19/2017)... ... ... Bone Solutions Inc. (BSI), an orthobiologics technology company located ... OsteoCrete® bone void filler is designed to assist with bone repair and generation, ... for bone health and development. , “We’re excited to bring this important orthopedic ...
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... of its Pflugerville- FM 685 facility. , “We are pleased to announce Dr. ... said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room – ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Davidson Institute for Talent ... on September 27 at a reception in Washington D.C. The recipients received $50,000, ... Music. , “I am honored to be a Davidson Fellow Laureate,” said Rishab ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... WAYNE, N.J. , Sept. 5, 2017 /PRNewswire/ ... technology, has created a vibrant charitable donation program ... funds and support congenital heart defect research by ... healthcare providers and the general public are encouraged ... and submit the completed artwork to the ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/28/2017)... , Aug. 28, 2017   Aesculight ®, a division of ... surgical lasers. Built on over 20 years of American veterinary laser ... New and Exclusive VetScalpel®Features and Enhancements ... Duclos, DVM, is excising a tumor with his new VetScalpel laser. Dr. ... Lynnwood, WA. ...
Breaking Medicine Technology: